4D pharma closed its business combination with Longevity Acquisition.
4D pharma’s existing Board of Directors and management team will continue to lead the combined company, while 4D will continue its operations in the discovery and development of live biotherapeutic products.
4D pharma received the $14.6 million cash held by Longevity. In addition, 4D pharma gains the proceeds of warrants to purchase Longevity shares worth up to $23 million.
4D American Depositary Shares are expected to start trading today on the Nasdaq under LBPS. 4D pharma ordinary shares will continue to be admitted to trading on AIM under DDDD. Read more.
